June 18, 2008 - Using combined positron emission tomography (PET) and computed tomography (CT) scanning of patients in the early stages of ovarian cancer can enable physicians to determine whether the cancer has spread to nearby lymph nodes without having to perform surgery, according to researchers at the SNM's 55th Annual Meeting.

"Our preliminary research indicates that using PET/CT scanning in this way could greatly improve quality of life for many patients with ovarian cancer," said Luca Guerra, doctor of nuclear medicine, San Gerardo Hospital, Monza, Italy, and lead researcher of the study, 18F-FDG PET/CT Usefulness in Initial Staging of Ovarian Cancer. "PET/CT scans could allow many women to forego major abdominal surgery to determine whether their cancer has spread. It's a much safer alternative for determining the stages of ovarian cancer."

In their research, Guerra and his team examined results of 30 women diagnosed with ovarian cancer who underwent PET/CT scanning before surgery to determine the stage of their disease. The results indicated that PET/CT staging was correct in 67 percent of patients and more than 98 percent accurate in scanning the lymph nodes of stage I and stage II ovarian cancer patients. These very promising results need to be confirmed in a larger patient population.

While most previous studies that examined the potential of PET technologies have not indicated a definite role in the staging of ovarian cancer, many of the studies involved very small groups of women, and the scanners used were simple PET scanners rather than state-of-the-art, combined PET/CT scanners.

While systematic lymphadenectomy - surgically removing all of the lymph nodes for testing rather than sampling a small number of the lymph nodes - is more accurate in determining whether the cancer has spread, the surgery takes longer, often requires blood transfusions and can result in life-threatening complications. If all early-stage ovarian cancer patients underwent lymphadenectomy, approximately 75 percent of the surgeries would prove unnecessary.

For more information: www.snm.org


Related Content

News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | PET Imaging

June 18, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 18, 2024
arrow
News | PET Imaging

June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 14, 2024
arrow
News | FDA

June 10, 2024 — Siemens Healthineers announces the Food and Drug Administration clearance of the Biograph Trinion, a ...

Time June 10, 2024
arrow
News | Radiology Business

May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on ...

Time May 14, 2024
arrow
News | Cardiac Imaging

April 23, 2024 — CDL Nuclear Technologies, a pioneer in advanced diagnostic solutions, is proud to announce the launch ...

Time April 23, 2024
arrow
News | FDA

January 23, 2024 — Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of syngo Virtual ...

Time January 23, 2024
arrow
News | Artificial Intelligence

January 23, 2024 — Quibim announced it has added an industry-leading cancer detection capability to its prostate tool ...

Time January 22, 2024
arrow
News | Radiology Business

December 27, 2023 — The American Roentgen Ray Society (ARRS) announced David M. Naeger, MD, as the 2024 ARRS ...

Time December 27, 2023
arrow
News | Radiopharmaceuticals and Tracers

December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., and Blue Earth Diagnostics, a Bracco ...

Time December 06, 2023
arrow
Subscribe Now